近十年来，乳腺癌新辅助化疗的应用日益扩大。对新辅助化疗反应良好的患者可受益于乳房及腋窝手术的降阶治疗。然而，乳房肿瘤及受累腋窝淋巴结应在化疗开始前进行标记。这有助于后续手术规划及术中评估疾病反应。
适应症：Breast Neoplasm、Chemotherapy Effect
入组条件
纳入标准
- All patients with cT1-3N1 invasive ductal carcinoma planned for neoadjuvant chemotherapy and/or target therapy
- mentally competent to give informed consent
- Agreed to proceed with curative operation after chemotherapy and tentatively keen for breast conservative surgery and targeted axillary dissection after neoadjuvant chemotherapy
- Radiologically 1-3 ipsilateral axillary lymph node metastases confirmed by cytology or biopsy
排除标准
- Presence of distant metastasis, inflammatory breast cancers, multi-centric breast cancers
- History of previous ipsilateral axillary surgery or irradiation
- Hypersensitivity to dextran compounds or iron
- Iron overload disease
- Pregnant or lactating patients
- Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder
- Mentally incompetent patients
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。